Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Death-associated Protein Kinase-1 Expression and Autophagy in Chronic Lymphocytic Leukemia Are Dependent on Activating Transcription Factor-6 and CCAAT/Enhancer-binding Protein-β.

Gade P, Kimball AS, DiNardo AC, Gangwal P, Ross DD, Boswell HS, Keay SK, Kalvakolanu DV.

J Biol Chem. 2016 Oct 14;291(42):22030-22042. Epub 2016 Sep 2.

2.

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1.

Natarajan K, Xie Y, Nakanishi T, Moreci RS, Jeyasuria P, Hussain A, Ross DD.

J Vis Exp. 2016 May 27;(111). doi: 10.3791/53827.

PMID:
27286290
3.

Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated BCRP/ABCG2 transcription in human cancer cells.

Xie Y, Nakanishi T, Natarajan K, Safren L, Hamburger AW, Hussain A, Ross DD.

Biochim Biophys Acta. 2015 Mar;1849(3):317-27. doi: 10.1016/j.bbagrm.2015.01.003. Epub 2015 Jan 21.

4.

Concomitant bone marrow involvement by plasma cell myeloma and primary myelodysplastic syndrome with biclonal complex chromosome anomalies.

Nanaji NM, Chen QC, Singh Z, Ross DD, Elman AH, Zou YS.

Leuk Lymphoma. 2015;56(8):2470-2. doi: 10.3109/10428194.2015.1004669. Epub 2015 Feb 24. No abstract available.

PMID:
25586604
5.

Bcrp1 transcription in mouse testis is controlled by a promoter upstream of a novel first exon (E1U) regulated by steroidogenic factor-1.

Xie Y, Natarajan K, Bauer KS, Nakanishi T, Beck WT, Moreci RS, Jeyasuria P, Hussain A, Ross DD.

Biochim Biophys Acta. 2013 Dec;1829(12):1288-99. doi: 10.1016/j.bbagrm.2013.10.008. Epub 2013 Nov 2.

6.

Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.

Gojo I, Tan M, Fang HB, Sadowska M, Lapidus R, Baer MR, Carrier F, Beumer JH, Anyang BN, Srivastava RK, Espinoza-Delgado I, Ross DD.

Clin Cancer Res. 2013 Apr 1;19(7):1838-51. doi: 10.1158/1078-0432.CCR-12-3165. Epub 2013 Feb 12.

7.

Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells.

Wu AM, Dalvi P, Lu X, Yang M, Riddick DS, Matthews J, Clevenger CV, Ross DD, Harper PA, Ito S.

Mol Pharmacol. 2013 Feb;83(2):377-88. doi: 10.1124/mol.112.082362. Epub 2012 Nov 13.

8.

Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells.

Hiwase DK, Saunders VA, Nievergall E, Ross DD, White DL, Hughes TP.

Haematologica. 2013 Jun;98(6):896-900. doi: 10.3324/haematol.2012.070268. Epub 2012 Oct 12.

9.

Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Natarajan K, Xie Y, Baer MR, Ross DD.

Biochem Pharmacol. 2012 Apr 15;83(8):1084-103. doi: 10.1016/j.bcp.2012.01.002. Epub 2012 Jan 11. Review.

10.

Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.

Nakanishi T, Ross DD.

Chin J Cancer. 2012 Feb;31(2):73-99. doi: 10.5732/cjc.011.10320. Epub 2011 Nov 18. Review.

11.

Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine.

Natarajan K, Xie Y, Nakanishi T, Beck WT, Bauer KS, Ross DD.

Biochim Biophys Acta. 2011 Jul;1809(7):295-305. doi: 10.1016/j.bbagrm.2011.06.004. Epub 2011 Jun 28.

12.

Creative solution for implementation of experiential, competency-based palliative care training for internal medicine residents.

Ross DD, Shpritz DW, Wolfsthal SD, Zimrin AB, Keay TJ, Fang HB, Schuetz CA, Stapleton LM, Weissman DE.

J Cancer Educ. 2011 Sep;26(3):436-43. doi: 10.1007/s13187-011-0235-x.

13.

Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.

Hou X, Huang F, Carboni JM, Flatten K, Asmann YW, Ten Eyck C, Nakanishi T, Tibodeau JD, Ross DD, Gottardis MM, Erlichman C, Kaufmann SH, Haluska P.

Mol Cancer Ther. 2011 Jan;10(1):117-25. doi: 10.1158/1535-7163.MCT-10-0438.

14.

A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells.

Tompkins LM, Li H, Li L, Lynch C, Xie Y, Nakanishi T, Ross DD, Wang H.

Biochem Pharmacol. 2010 Dec 1;80(11):1754-61. doi: 10.1016/j.bcp.2010.08.016. Epub 2010 Sep 9.

15.

Effects of an oral health education program for pregnant women.

Cardenas LM, Ross DD.

J Tenn Dent Assoc. 2010 Spring;90(2):23-6; quiz 26-7.

PMID:
20698433
16.

Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors.

Fan X, Ross DD, Arakawa H, Ganapathy V, Tamai I, Nakanishi T.

Biochem Pharmacol. 2010 Sep 15;80(6):811-8. doi: 10.1016/j.bcp.2010.05.021. Epub 2010 May 26.

PMID:
20510678
17.

Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2).

Tan KP, Wang B, Yang M, Boutros PC, Macaulay J, Xu H, Chuang AI, Kosuge K, Yamamoto M, Takahashi S, Wu AM, Ross DD, Harper PA, Ito S.

Mol Pharmacol. 2010 Aug;78(2):175-85. doi: 10.1124/mol.110.065078. Epub 2010 May 11.

18.

Methods to evaluate transporter activity in cancer.

Nakanishi T, Ross DD, Mitsuoka K.

Methods Mol Biol. 2010;637:105-20. doi: 10.1007/978-1-60761-700-6_5.

PMID:
20419431
19.

Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling.

Nakanishi T, Chumsri S, Khakpour N, Brodie AH, Leyland-Jones B, Hamburger AW, Ross DD, Burger AM.

Br J Cancer. 2010 Mar 2;102(5):815-26. doi: 10.1038/sj.bjc.6605553. Epub 2010 Feb 9.

20.

Impact of breast cancer resistance protein on cancer treatment outcomes.

Ross DD, Nakanishi T.

Methods Mol Biol. 2010;596:251-90. doi: 10.1007/978-1-60761-416-6_12.

PMID:
19949928
21.

Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.

Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK.

Mol Cancer Ther. 2009 Jun;8(6):1596-605. doi: 10.1158/1535-7163.MCT-08-1004. Epub 2009 Jun 9.

22.

Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.

Shiozawa K, Nakanishi T, Tan M, Fang HB, Wang WC, Edelman MJ, Carlton D, Gojo I, Sausville EA, Ross DD.

Clin Cancer Res. 2009 Mar 1;15(5):1698-707. doi: 10.1158/1078-0432.CCR-08-1587. Epub 2009 Feb 17.

23.

Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses.

Fang HB, Ross DD, Sausville E, Tan M.

Stat Med. 2008 Jul 20;27(16):3071-83. doi: 10.1002/sim.3204.

PMID:
18186545
24.

The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells.

Xie Y, Xu K, Linn DE, Yang X, Guo Z, Shimelis H, Nakanishi T, Ross DD, Chen H, Fazli L, Gleave ME, Qiu Y.

J Biol Chem. 2008 Feb 8;283(6):3349-56. Epub 2007 Dec 5.

25.

Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells.

Wang H, Lee EW, Zhou L, Leung PC, Ross DD, Unadkat JD, Mao Q.

Mol Pharmacol. 2008 Mar;73(3):845-54. Epub 2007 Nov 27.

26.

Mechanisms of resistance and adaptation to thapsigargin in androgen-independent prostate cancer PC3 and DU145 cells.

Lee DI, Sumbilla C, Lee M, Natesavelalar C, Klein MG, Ross DD, Inesi G, Hussain A.

Arch Biochem Biophys. 2007 Aug 1;464(1):19-27. Epub 2007 Apr 16.

PMID:
17475205
27.

Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL.

Fandy TE, Ross DD, Gore SD, Srivastava RK.

Cancer Chemother Pharmacol. 2007 Aug;60(3):313-9. Epub 2006 Dec 23.

PMID:
17187253
28.

Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage.

Nakanishi T, Bailey-Dell KJ, Hassel BA, Shiozawa K, Sullivan DM, Turner J, Ross DD.

Cancer Res. 2006 May 15;66(10):5007-11. Erratum in: Cancer Res. 2007 May 1;67(9):4535.

30.

Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.

Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, Ross DD, Mao Q.

Cancer Chemother Pharmacol. 2006 Sep;58(3):374-83. Epub 2006 Jan 11.

PMID:
16404634
31.

Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.

Karp JE, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella TS, Greer J, Briel J, Smith BD, Gore SD, Tidwell ML, Ross DD, Wright JJ, Colevas AD, Bauer KS.

Clin Cancer Res. 2005 Dec 1;11(23):8403-12.

32.

Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.

Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK.

Int J Mol Med. 2005 Dec;16(6):1125-38.

PMID:
16273296
33.

Long-term evaluation of required coursework in palliative and end-of-life care for medical students.

Ross DD, Shpritz D, Hull MM, Goloubeva O.

J Palliat Med. 2005 Oct;8(5):962-74.

PMID:
16238509
34.

Message for mid-term, 2005.

Ross DD.

J Cancer Educ. 2005 Summer;20(2):65-6. No abstract available.

PMID:
16083366
36.

The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.

Zhang Y, Wang XW, Jelovac D, Nakanishi T, Yu MH, Akinmade D, Goloubeva O, Ross DD, Brodie A, Hamburger AW.

Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9890-5. Epub 2005 Jun 30.

37.

Adult education program in palliative care for nursing facility physicians: design and pilot test.

Keay TJ, Alexander C, McNally K, Crusse B, Eger RE, Hawtin C, Lowitt NR, Ross DD.

J Palliat Med. 2000 Winter;3(4):457-63.

PMID:
15859698
39.

Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.

Ee PL, He X, Ross DD, Beck WT.

Mol Cancer Ther. 2004 Dec;3(12):1577-83.

40.

Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors.

Garimella TS, Ross DD, Eiseman JL, Mondick JT, Joseph E, Nakanishi T, Bates SE, Bauer KS.

Cancer Chemother Pharmacol. 2005 Feb;55(2):101-9. Epub 2004 Oct 1.

PMID:
15580504
41.

Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival.

Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Ford LA, Greco WR, Wetzler M, Ross DD, Baer MR.

Br J Haematol. 2004 Nov;127(4):392-8.

PMID:
15521915
42.

Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome.

Ross DD.

Best Pract Res Clin Haematol. 2004 Dec;17(4):641-51. Review.

PMID:
15494300
43.

Development of required postgraduate palliative care training for internal medicine residents and medical oncology fellows.

Ross DD, Shpritz D, Alexander CS, Carter K, Edelman MJ, Friedley N, Hemani A, Keay TJ, Roy SC, Silverman H, Tasker DJ, Timmel D, Schwartz J, Wolfsthal SD.

J Cancer Educ. 2004 Summer;19(2):81-7.

PMID:
15456662
44.
45.

Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function.

Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Greco WR, Ross DD, Baer MR.

Leukemia. 2004 Jul;18(7):1252-7.

PMID:
15208643
46.
47.

The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme.

Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP, Schuetz JD.

J Biol Chem. 2004 Jun 4;279(23):24218-25. Epub 2004 Mar 24.

48.

Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene.

Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD, Beck WT.

Cancer Res. 2004 Feb 15;64(4):1247-51.

49.

Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis.

Nakanishi T, Doyle LA, Hassel B, Wei Y, Bauer KS, Wu S, Pumplin DW, Fang HB, Ross DD.

Mol Pharmacol. 2003 Dec;64(6):1452-62.

50.

Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.

Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S.

Int J Cancer. 2004 Jan 1;108(1):146-51.

Supplemental Content

Support Center